Pacific Biosciences Launches New Sequencing Platform Based on Its SMRT Technology

Sequel(TM) System Offers Significantly Higher Throughput, Reducing Project Costs and Timelines

MENLO PARK, Calif., Sept. 30, 2015 -- Pacific Biosciences of California, Inc., (PACB) a pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT^(R)) Technology, today announced it has launched a new nucleic acid sequencing platform. The Sequel(TM) System provides higher throughput, more scalability, a reduced footprint and lower sequencing project costs compared to the PacBio^(R) RS II System, while maintaining the existing benefits of the company's SMRT Technology. Pacific Biosciences will showcase the new product at the American Society of Human Genetics annual meeting taking place in Baltimore, Maryland beginning October 6, 2015.

Published: 01 October 2015

Written by Editor

Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 (Bucillamine) in the Treatment of Acute Gout Flares

TORONTO, ONTARIO--(Sept. 30, 2015) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) today announced interim results from the ongoing Phase 2a clinical study evaluating REV-002 (Bucillamine) as an oral anti-inflammatory agent for the treatment of acute gout arthritis flares.

The interim results from the Phase 2a clinical study yielded the following key findings in 29 subjects treated for acute gout flare that had completed the 7-day treatment period:

In Arm A (oral Bucillamine - 900mg over 7 days), 25% (2/8 subjects) had a ≥ 50% reduction in target joint pain score from baseline at 72 hours post-dose;

Published: 30 September 2015

Written by Editor

TSX Venture Up on News Project Update

Read more: Revive Therapeutics Ltd ( RVV )

Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics

Novavax’ Fifth Positive Top-Line Clinical Trial Announcement of the 3rd Quarter

GAITHERSBURG, Md., Sept. 29, 2015 -- Novavax, Inc., (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced positive top-line data from a Phase 1 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in healthy children.

The trial was a randomized, observer-blinded, Phase 1 study to evaluate the safety and immunogenicity of the RSV F Vaccine, with one or two doses, with or without aluminum phosphate adjuvant, in healthy pediatric participants two to six years of age. The trial's primary goal was to evaluate safety in this population and immunogenicity as measured by concentrations of serum IgG antibodies to the RSV fusion, or F-protein, palivizumab-competing antibody (PCA) titers and RSV microneutralization titers. Novavax concluded this trial’s enrollment with a smaller than planned cohort so dosing could be completed ahead of the 2014-2015 RSV season.

Published: 30 September 2015

Written by Editor

Nasdaq Up on News Project Update

MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.

Contract Highlights Product's Merit and Therapeutic Impact, as well as Potential Role in Mass Casualty Preparedness

YAVNE, Israel, Sept. 30, 2015 -- MediWound Ltd. (MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company a contract valued at up to $112 million. The contract is for the advancement of the development and manufacturing, as well as the procurement of NexoBrid^(R), the Company's proprietary pharmaceutical product for enzymatic removal of eschar in adults with deep-partial and full-thickness thermal burns, as a medical countermeasure as part of BARDA preparedness for mass casualty events.

Published: 30 September 2015

Written by Editor

Nasdaq New Product or Order Up on News

Can-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on October 10, 2015

Late Breaking Session features very important papers with high impact factors

PETACH TIKVA, Israel, Sept. 29, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the Company's CEO, Dr. Pnina Fishman will present data at the 24^th European Academy of Dermatology and Venereology's (EADV) Congress in Copenhagen, Denmark on Saturday, October 10, 2015.

Published: 29 September 2015

Written by Editor

AMEX Up on News Project Update

Page 113 of 246

Pacific Biosciences of California Inc ( PACB )

Pacific Biosciences Launches New Sequencing Platform Based on Its SMRT Technology

Revive Therapeutics Ltd ( RVV )

Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 (Bucillamine) in the Treatment of Acute Gout Flares

Novavax Inc ( NVAX )

Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics

MediWound Ltd ( MDWD )

MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.

Can-Fite BioPharma Ltd ( CANF )

Can-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on October 10, 2015